HRP20191304T4 - Antigljivični pripravak i postupci liječenja - Google Patents
Antigljivični pripravak i postupci liječenja Download PDFInfo
- Publication number
- HRP20191304T4 HRP20191304T4 HRP20191304TT HRP20191304T HRP20191304T4 HR P20191304 T4 HRP20191304 T4 HR P20191304T4 HR P20191304T T HRP20191304T T HR P20191304TT HR P20191304 T HRP20191304 T HR P20191304T HR P20191304 T4 HRP20191304 T4 HR P20191304T4
- Authority
- HR
- Croatia
- Prior art keywords
- preparation
- topical
- antifungal agent
- preparation according
- infection
- Prior art date
Links
- 230000000699 topical effect Effects 0.000 title claims 11
- 229940121375 antifungal agent Drugs 0.000 title claims 7
- 238000000034 method Methods 0.000 title claims 4
- 239000000203 mixture Substances 0.000 title claims 2
- 230000000843 anti-fungal effect Effects 0.000 title 1
- 238000002360 preparation method Methods 0.000 claims 16
- 239000003429 antifungal agent Substances 0.000 claims 6
- 229920000642 polymer Polymers 0.000 claims 4
- VAZJLPXFVQHDFB-UHFFFAOYSA-N 1-(diaminomethylidene)-2-hexylguanidine Polymers CCCCCCN=C(N)N=C(N)N VAZJLPXFVQHDFB-UHFFFAOYSA-N 0.000 claims 2
- 206010017533 Fungal infection Diseases 0.000 claims 2
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims 2
- 229920002413 Polyhexanide Polymers 0.000 claims 2
- 239000000853 adhesive Substances 0.000 claims 2
- 230000001070 adhesive effect Effects 0.000 claims 2
- 125000004122 cyclic group Chemical group 0.000 claims 2
- 238000004519 manufacturing process Methods 0.000 claims 2
- 239000002105 nanoparticle Substances 0.000 claims 2
- DOMXUEMWDBAQBQ-WEVVVXLNSA-N terbinafine Chemical compound C1=CC=C2C(CN(C\C=C\C#CC(C)(C)C)C)=CC=CC2=C1 DOMXUEMWDBAQBQ-WEVVVXLNSA-N 0.000 claims 2
- 229960002722 terbinafine Drugs 0.000 claims 2
- XMAYWYJOQHXEEK-OZXSUGGESA-N (2R,4S)-ketoconazole Chemical compound C1CN(C(=O)C)CCN1C(C=C1)=CC=C1OC[C@@H]1O[C@@](CN2C=NC=C2)(C=2C(=CC(Cl)=CC=2)Cl)OC1 XMAYWYJOQHXEEK-OZXSUGGESA-N 0.000 claims 1
- VHVPQPYKVGDNFY-DFMJLFEVSA-N 2-[(2r)-butan-2-yl]-4-[4-[4-[4-[[(2r,4s)-2-(2,4-dichlorophenyl)-2-(1,2,4-triazol-1-ylmethyl)-1,3-dioxolan-4-yl]methoxy]phenyl]piperazin-1-yl]phenyl]-1,2,4-triazol-3-one Chemical compound O=C1N([C@H](C)CC)N=CN1C1=CC=C(N2CCN(CC2)C=2C=CC(OC[C@@H]3O[C@](CN4N=CN=C4)(OC3)C=3C(=CC(Cl)=CC=3)Cl)=CC=2)C=C1 VHVPQPYKVGDNFY-DFMJLFEVSA-N 0.000 claims 1
- APKFDSVGJQXUKY-KKGHZKTASA-N Amphotericin-B Natural products O[C@H]1[C@@H](N)[C@H](O)[C@@H](C)O[C@H]1O[C@H]1C=CC=CC=CC=CC=CC=CC=C[C@H](C)[C@@H](O)[C@@H](C)[C@H](C)OC(=O)C[C@H](O)C[C@H](O)CC[C@@H](O)[C@H](O)C[C@H](O)C[C@](O)(C[C@H](O)[C@H]2C(O)=O)O[C@H]2C1 APKFDSVGJQXUKY-KKGHZKTASA-N 0.000 claims 1
- 208000007163 Dermatomycoses Diseases 0.000 claims 1
- 206010017543 Fungal skin infection Diseases 0.000 claims 1
- 208000031888 Mycoses Diseases 0.000 claims 1
- 206010034016 Paronychia Diseases 0.000 claims 1
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 claims 1
- APKFDSVGJQXUKY-INPOYWNPSA-N amphotericin B Chemical compound O[C@H]1[C@@H](N)[C@H](O)[C@@H](C)O[C@H]1O[C@H]1/C=C/C=C/C=C/C=C/C=C/C=C/C=C/[C@H](C)[C@@H](O)[C@@H](C)[C@H](C)OC(=O)C[C@H](O)C[C@H](O)CC[C@@H](O)[C@H](O)C[C@H](O)C[C@](O)(C[C@H](O)[C@H]2C(O)=O)O[C@H]2C1 APKFDSVGJQXUKY-INPOYWNPSA-N 0.000 claims 1
- 229960003942 amphotericin b Drugs 0.000 claims 1
- 239000003963 antioxidant agent Substances 0.000 claims 1
- 239000012752 auxiliary agent Substances 0.000 claims 1
- YBHILYKTIRIUTE-UHFFFAOYSA-N berberine Chemical compound C1=C2CC[N+]3=CC4=C(OC)C(OC)=CC=C4C=C3C2=CC2=C1OCO2 YBHILYKTIRIUTE-UHFFFAOYSA-N 0.000 claims 1
- 229940093265 berberine Drugs 0.000 claims 1
- QISXPYZVZJBNDM-UHFFFAOYSA-N berberine Natural products COc1ccc2C=C3N(Cc2c1OC)C=Cc4cc5OCOc5cc34 QISXPYZVZJBNDM-UHFFFAOYSA-N 0.000 claims 1
- 239000011230 binding agent Substances 0.000 claims 1
- 230000015572 biosynthetic process Effects 0.000 claims 1
- 239000000872 buffer Substances 0.000 claims 1
- 239000004202 carbamide Substances 0.000 claims 1
- 239000003795 chemical substances by application Substances 0.000 claims 1
- 239000006071 cream Substances 0.000 claims 1
- 239000003995 emulsifying agent Substances 0.000 claims 1
- 239000003205 fragrance Substances 0.000 claims 1
- 235000011187 glycerol Nutrition 0.000 claims 1
- 229960004130 itraconazole Drugs 0.000 claims 1
- 229960004125 ketoconazole Drugs 0.000 claims 1
- 229960000988 nystatin Drugs 0.000 claims 1
- VQOXZBDYSJBXMA-NQTDYLQESA-N nystatin A1 Chemical compound O[C@H]1[C@@H](N)[C@H](O)[C@@H](C)O[C@H]1O[C@H]1/C=C/C=C/C=C/C=C/CC/C=C/C=C/[C@H](C)[C@@H](O)[C@@H](C)[C@H](C)OC(=O)C[C@H](O)C[C@H](O)C[C@H](O)CC[C@@H](O)[C@H](O)C[C@](O)(C[C@H](O)[C@H]2C(O)=O)O[C@H]2C1 VQOXZBDYSJBXMA-NQTDYLQESA-N 0.000 claims 1
- 239000003921 oil Substances 0.000 claims 1
- 239000002674 ointment Substances 0.000 claims 1
- 239000000843 powder Substances 0.000 claims 1
- 239000003755 preservative agent Substances 0.000 claims 1
- 206010040872 skin infection Diseases 0.000 claims 1
- 239000007921 spray Substances 0.000 claims 1
- 230000009885 systemic effect Effects 0.000 claims 1
- BWMISRWJRUSYEX-SZKNIZGXSA-N terbinafine hydrochloride Chemical compound Cl.C1=CC=C2C(CN(C\C=C\C#CC(C)(C)C)C)=CC=CC2=C1 BWMISRWJRUSYEX-SZKNIZGXSA-N 0.000 claims 1
- 201000004647 tinea pedis Diseases 0.000 claims 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/51—Nanocapsules; Nanoparticles
- A61K9/5107—Excipients; Inactive ingredients
- A61K9/513—Organic macromolecular compounds; Dendrimers
- A61K9/5146—Organic macromolecular compounds; Dendrimers obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyamines, polyanhydrides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
- A61K9/0021—Intradermal administration, e.g. through microneedle arrays, needleless injectors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/51—Nanocapsules; Nanoparticles
- A61K9/5107—Excipients; Inactive ingredients
- A61K9/5123—Organic compounds, e.g. fats, sugars
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M37/00—Other apparatus for introducing media into the body; Percutany, i.e. introducing medicines into the body by diffusion through the skin
- A61M37/0015—Other apparatus for introducing media into the body; Percutany, i.e. introducing medicines into the body by diffusion through the skin by using microneedles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/10—Antimycotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M37/00—Other apparatus for introducing media into the body; Percutany, i.e. introducing medicines into the body by diffusion through the skin
- A61M37/0015—Other apparatus for introducing media into the body; Percutany, i.e. introducing medicines into the body by diffusion through the skin by using microneedles
- A61M2037/0023—Drug applicators using microneedles
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B82—NANOTECHNOLOGY
- B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
- B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Dermatology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Physics & Mathematics (AREA)
- Optics & Photonics (AREA)
- Nanotechnology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Molecular Biology (AREA)
- Emergency Medicine (AREA)
- Medical Informatics (AREA)
- Anesthesiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Hematology (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Claims (11)
1. Pripravak za topikalnu primjenu za liječenje gljivične infekcije nokta ili kože koji sadrži polimer i antigljivično sredstvo, naznačen time što polimer sadrži linearni i/ili razgranati ili ciklički polimonogvanid/poligvanidin, polibigvanid, i antigljivično sredstvo koje sadrži Terbinafin, te pri čemu je pripravak u obliku nanočestica.
2. Topikalni pripravak prema patentnom zahtjevu 1, naznačen time što polimer sadrži poliheksametilen bigvanid (PHMB).
3. Topikalni pripravak prema bilo kojem prethodnom patentnom zahtjevu, naznačen time što je antigljivično sredstvo prisutno u količini doze unutar pripravka, koja je manja od terapijski učinkovite sistemske doze antigljivičnog sredstva.
4. Topikalni pripravak prema bilo kojem prethodnom patentnom zahtjevu, naznačen time što pripravak nadalje sadrži jednu ili više sljedećih komponenata: pufere, pomoćna sredstva, veziva, ulja, vodu, emulgatore, glicerin, antioksidante, konzervanse i mirise, te po izboru, nadalje sadrži ureu.
5. Topikalni pripravak prema bilo kojem prethodnom patentnom zahtjevu, naznačen time što gljivična infekcija kože obuhvaća atletsko stopalo ili dermatofitnu infekciju i/ili infekciju kvaščevom gljivicom.
6. Topikalni pripravak prema bilo kojem prethodnom patentnom zahtjevu, naznačen time što antigljivično sredstvo sadrži jedno ili više daljnjih sredstava odabranih iz slijedeće skupine: nistatin, ketokonazol, amfotericin B, itrakonazol ili berberin.
7. Topikalni pripravak prema bilo kojem prethodnom patentnom zahtjevu, naznačen time što je pripravak u obliku kreme, masti, spreja ili praha.
8. Topikalni pripravak prema bilo kojem prethodnom patentnom zahtjevu, naznačen time što se pripravak primjenjuje pomoću niza mikro igala, koje su po izboru, ugrađene u ljepljivi flaster.
9. Postupak za proizvodnju pripravka za topikalnu primjenu za liječenje gljivične infekcije nokta ili kože naznačen time što obuhvaća miješanje polimera koji sadrži linearni i/ili razgranati ili ciklički polimonogvanid/poligvanidin, polibigvanid, i antigljivičnog sredstva koje sadrži Terbinafin, pod uvjetima prikladnim za omogućavanje formiranja nanočestica.
10. Postupak prema patentnom zahtjevu 9, naznačen time što se postupak koristi za proizvodnju pripravka prema bilo kojem od patentnih zahtjeva 1 do 8.
11. Topikalni pripravak prema patentnim zahtjevima 1 do 8, naznačen time što se pripravak upotrebljava u kombinaciji s nizom mikro igala, pri čemu je po izboru, niz mikro igala ugrađen u ljepljivi flaster.
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB1317005.5A GB201317005D0 (en) | 2013-09-25 | 2013-09-25 | Composition and methods of treatment |
| GBGB1320723.8A GB201320723D0 (en) | 2013-09-25 | 2013-11-25 | Composition and methods of treatment |
| PCT/GB2014/052911 WO2015044669A1 (en) | 2013-09-25 | 2014-09-25 | Antifungal topical composition and methods of treatment |
| EP14781264.8A EP3049056B2 (en) | 2013-09-25 | 2014-09-25 | Antifungal topical composition and methods of treatment |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| HRP20191304T1 HRP20191304T1 (hr) | 2019-10-18 |
| HRP20191304T4 true HRP20191304T4 (hr) | 2022-07-22 |
Family
ID=49553377
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20191304TT HRP20191304T4 (hr) | 2013-09-25 | 2014-09-25 | Antigljivični pripravak i postupci liječenja |
Country Status (16)
| Country | Link |
|---|---|
| US (2) | US11185511B2 (hr) |
| EP (3) | EP3049056B2 (hr) |
| JP (2) | JP6581569B2 (hr) |
| CN (1) | CN105579028B (hr) |
| CY (1) | CY1123414T1 (hr) |
| DK (1) | DK3049056T4 (hr) |
| ES (2) | ES2738662T5 (hr) |
| GB (2) | GB201317005D0 (hr) |
| HR (1) | HRP20191304T4 (hr) |
| HU (1) | HUE044589T2 (hr) |
| LT (1) | LT3049056T (hr) |
| PL (1) | PL3049056T5 (hr) |
| PT (1) | PT3049056T (hr) |
| RS (1) | RS59211B2 (hr) |
| SI (1) | SI3049056T2 (hr) |
| WO (1) | WO2015044669A1 (hr) |
Families Citing this family (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB201317005D0 (en) * | 2013-09-25 | 2013-11-06 | Blueberry Therapeutics Ltd | Composition and methods of treatment |
| US11110071B2 (en) * | 2015-06-19 | 2021-09-07 | Global Health Solutions Llc | Petrolatum-based PHMB compositions and methods of treatment for onychomycosis |
| GB201511799D0 (en) | 2015-07-06 | 2015-08-19 | Blueberry Therapeutics Ltd | Composition and methods of treatment |
| CA3018629A1 (en) * | 2016-03-24 | 2017-09-28 | Locate Therapeutics Limited | Scaffolding material, methods and uses |
| GB201605127D0 (en) | 2016-03-25 | 2016-05-11 | Blueberry Therapeutics Ltd | Composition and methods of treatment |
| JP6310977B2 (ja) * | 2016-09-07 | 2018-04-11 | 株式会社日本総合研究所 | 爪用シール及びシールシート |
| WO2018162271A1 (en) | 2017-03-05 | 2018-09-13 | Rita Dobmeyer | Nanoparticles for the treatment of macular degeneration |
| GB201710491D0 (en) | 2017-06-30 | 2017-08-16 | Blueberry Therapeutics Ltd | Composition and methods of treatment |
| KR102060138B1 (ko) * | 2018-05-30 | 2019-12-27 | 연세대학교 산학협력단 | 안구용 마이크로니들 주사의 제조방법 |
| GB201810925D0 (en) * | 2018-07-03 | 2018-08-15 | Blueberry Therapeutics Ltd | Compositions and methods of treatment |
| GB201810923D0 (en) * | 2018-07-03 | 2018-08-15 | Blueberry Therapeutics Ltd | Compositions and method of treatment |
| CA3127079A1 (en) * | 2019-01-16 | 2020-07-23 | Global Health Solutions Llc | Petrolatum-based phmb compositions and methods of treatment for onychomycosis |
| GB201908229D0 (en) * | 2019-06-10 | 2019-07-24 | Univ College Cork National Univ Of Ireland | Microneedles and methods for the manufacture thereof |
| CN110898075B (zh) * | 2019-12-27 | 2021-08-03 | 温海 | 聚六亚甲基双胍在制备抑制和/或杀灭犬小孢子菌的药物中的应用 |
| CN111067897A (zh) * | 2020-01-20 | 2020-04-28 | 中山大学 | 一种抗真菌的组合物及其应用 |
| EP4110305A1 (en) * | 2020-02-26 | 2023-01-04 | Biosergen AS | Pharmaceutical compositions of a therapeutic polyene macrolide and methods of their use |
| CN111588689B (zh) * | 2020-06-20 | 2023-08-11 | 温州医科大学 | 一种角膜微创可溶性微针贴片及其制备方法与应用 |
| CN112168845A (zh) * | 2020-11-13 | 2021-01-05 | 郑虹 | 一种用于治疗手足癣的药物软膏及其制备方法 |
| DE102021118997A1 (de) * | 2021-07-22 | 2023-01-26 | Lts Lohmann Therapie-Systeme Ag. | Mikronadelarray mit Antiseptika |
| CN113567217A (zh) * | 2021-07-27 | 2021-10-29 | 肖波 | 一种妇科荧光染色液 |
| WO2023154464A1 (en) * | 2022-02-11 | 2023-08-17 | Fairleigh Dickinson University | Locally administered compositions and methods of use thereof |
| KR102597564B1 (ko) * | 2023-03-03 | 2023-11-03 | 장병모 | 조갑 및 피부 백선의 예방 또는 치료용 약학적 조성물 |
Family Cites Families (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2761886B1 (fr) * | 1997-04-14 | 2000-05-05 | Virbac Sa | Compositions contenant au moins un polymere cationique et au moins une molecule active contenue dans au moins un vecteur micro ou nanoparticulaire, et leur utilisation pour le traitement de surfaces vivantes ou inertes |
| US20020009491A1 (en) | 2000-02-14 | 2002-01-24 | Rothbard Jonathan B. | Compositions and methods for enhancing drug delivery across biological membranes and tissues |
| NZ542904A (en) * | 2003-03-21 | 2009-04-30 | Nexmed Holdings Inc | Antifungal nail coat and method of use |
| US7871649B2 (en) * | 2003-07-17 | 2011-01-18 | The Trustees Of Columbia University In The City Of New York | Antimicrobial compositions containing synergistic combinations of quaternary ammonium compounds and essential oils and/or constituents thereof |
| US20050238672A1 (en) * | 2004-04-27 | 2005-10-27 | Nimni Marcel E | Antifungal drug delivery |
| AU2005247328B2 (en) * | 2004-05-03 | 2011-03-10 | Shalon Ventures, L.P. | Polycationic antimicrobial therapeutic |
| WO2006138719A2 (en) * | 2005-06-17 | 2006-12-28 | Georgia Tech Research Corporation | Coated microstructures and method of manufacture thereof |
| CN101208129B (zh) * | 2005-06-27 | 2011-03-30 | 3M创新有限公司 | 微针药筒组件及其施放方法 |
| EP1909868A1 (en) * | 2005-07-25 | 2008-04-16 | Nanotechnology Victoria PTY Ltd | Microarray device |
| US20070249546A1 (en) * | 2006-04-22 | 2007-10-25 | Sawaya Assad S | Ophthalmic and related aqueous solutions containing antifungal agents, uses therefor and methods for preparing them |
| EP2054339A4 (en) | 2006-08-11 | 2011-08-03 | Panacea Biotec Ltd | PARTICULARS FOR ACTIVE INHIBITION, MANUFACTURING METHOD AND COMPOSITIONS THEREOF |
| EP2073848B1 (en) * | 2006-10-05 | 2013-08-28 | The Johns Hopkins University | Water-dispersible oral, parenteral, and topical formulations for poorly water soluble drugs using smart polymeric nanoparticles |
| US20100021530A1 (en) * | 2008-07-25 | 2010-01-28 | Innovation Biomedical Devices, Inc. | Enhanced trans-keratin drug delivery |
| CN101724284B (zh) * | 2008-10-31 | 2012-06-27 | 中国石油化工股份有限公司 | 一种抗菌热塑性塑料组合物及其制备方法 |
| JP5408592B2 (ja) | 2010-03-19 | 2014-02-05 | コスメディ製薬株式会社 | マイクロニードルの迅速溶解法 |
| JP2012235899A (ja) | 2011-05-12 | 2012-12-06 | Bioserentack Co Ltd | 大量の目的物質を皮膚内へデリバリーするためのマイクロニードル・アレイ・チップ |
| BR112013033239A2 (pt) | 2011-06-22 | 2016-09-06 | Vyome Biosciences | pró-farmácos de conjugado baseado em atifungicos e antibacterianos |
| GB201117538D0 (en) | 2011-10-11 | 2011-11-23 | Royal Veterinary College The | Methods |
| EP2664327A1 (en) * | 2012-05-14 | 2013-11-20 | Almirall S.A. | Topical pharmaceutical compositions comprising terbinafide and urea |
| GB201317005D0 (en) * | 2013-09-25 | 2013-11-06 | Blueberry Therapeutics Ltd | Composition and methods of treatment |
-
2013
- 2013-09-25 GB GBGB1317005.5A patent/GB201317005D0/en not_active Ceased
- 2013-11-25 GB GBGB1320723.8A patent/GB201320723D0/en not_active Ceased
-
2014
- 2014-09-25 PL PL14781264.8T patent/PL3049056T5/pl unknown
- 2014-09-25 RS RS20190917A patent/RS59211B2/sr unknown
- 2014-09-25 EP EP14781264.8A patent/EP3049056B2/en active Active
- 2014-09-25 HR HRP20191304TT patent/HRP20191304T4/hr unknown
- 2014-09-25 EP EP20209656.6A patent/EP3854380A1/en active Pending
- 2014-09-25 LT LTEP14781264.8T patent/LT3049056T/lt unknown
- 2014-09-25 HU HUE14781264 patent/HUE044589T2/hu unknown
- 2014-09-25 EP EP19153995.6A patent/EP3501498B1/en active Active
- 2014-09-25 WO PCT/GB2014/052911 patent/WO2015044669A1/en active Application Filing
- 2014-09-25 SI SI201431280T patent/SI3049056T2/sl unknown
- 2014-09-25 PT PT14781264T patent/PT3049056T/pt unknown
- 2014-09-25 US US15/023,602 patent/US11185511B2/en active Active
- 2014-09-25 ES ES14781264T patent/ES2738662T5/es active Active
- 2014-09-25 ES ES19153995T patent/ES2859518T3/es active Active
- 2014-09-25 CN CN201480052228.3A patent/CN105579028B/zh active Active
- 2014-09-25 JP JP2016516087A patent/JP6581569B2/ja active Active
- 2014-09-25 DK DK14781264.8T patent/DK3049056T4/da active
-
2019
- 2019-07-24 CY CY20191100783T patent/CY1123414T1/el unknown
- 2019-08-30 JP JP2019158280A patent/JP7028836B2/ja active Active
-
2021
- 2021-10-27 US US17/512,139 patent/US20220133640A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20191304T4 (hr) | Antigljivični pripravak i postupci liječenja | |
| JP2016536271A5 (hr) | ||
| HRP20200431T1 (hr) | Hidrogel na bazi polimera | |
| WO2013174615A3 (en) | Personal care composition comprising a colling active and a copolymer comprising acrylamidopropyltrimonium chloride | |
| CO2018001375A2 (es) | Composiciones de retinoides tópicos | |
| BR112015010772A2 (pt) | composição de enxágue tópica, uso de uma composição e método para tratar ou melhorar a pele de um indivíduo contra a acne | |
| WO2014030770A3 (en) | Copolymer having carbosiloxane dendrimer structure and hydrophilic group | |
| WO2013177594A3 (en) | Xylitol-based anti-mucosal compositions and related methods and compositions | |
| HK1208812A1 (en) | A topical composition comprising a film-forming polymer for delivering an active ingredient to skin | |
| BR112018013979A2 (pt) | composições em gel para liberação transdérmica para maximizar as concentrações de fármacos no estrato córneo e no soro e métodos de uso dos mesmos | |
| WO2013079605A3 (en) | Polymeric drug-delivery material, method for manufacturing thereof and method for delivery of a drug-delivery composition | |
| WO2011088333A3 (en) | Solid-forming local anesthetic formulations for pain control | |
| BR112015005339A8 (pt) | uso de óleo de semente de fruta milagrosa como um ingrediente ativo | |
| BR112014026427A2 (pt) | formulação antiaderente incluindo um composto de amônio quaternário e um álcool graxo | |
| WO2014121048A3 (en) | Topical compositions and methods for making and using same | |
| SA113340494B1 (ar) | تركيبة لعلاج اضطرابات أيضية | |
| IL273329A (en) | Modulation of hepatic-hepatic epidermal growth factor activity to heal the eardrum membrane | |
| ECSP15033898A (es) | Composición antifúngica tópica para el tratamiento de onicomicosis | |
| WO2014178789A9 (en) | Topical composition and carrier for administration of pharmaceutically or cosmetically active ingredients | |
| SG10201908690WA (en) | Novel method of use and compositions | |
| BR112014004737A2 (pt) | composto de composição de cloridrato de ambroxol e método de preparação do composto | |
| JP2019509281A5 (hr) | ||
| WO2015100348A8 (en) | Keloid reduction using topical allantoin | |
| ES2672314R1 (es) | Ingrediente farmacéutico activo (ifa) oleoso para el tratamiento de afecciones de la piel, composiciones que lo comprenden y su uso para prepararlas | |
| WO2014091146A3 (fr) | Utilisation cosmetique d'un extrait de germe de caroube en tant qu'agent actif amincissant |